Reuters reports the GLP-1 antitrust dismissal

A federal judge in San Antonio has dismissed an antitrust lawsuit that accused Eli Lilly and Novo Nordisk of illegally blocking patient access to compounded versions of their GLP-1 weight-loss and diabetes drugs ^[1]. U.S. District Judge Micaela Alvarez granted requests from both drugmakers to throw out the case, which was filed in January by compounding pharmacy Strive Specialties ^[1].

Strive had argued that Lilly and Novo struck exclusive deals with major telehealth providers that stopped doctors on those platforms from prescribing compounded GLP-1 drugs, which the pharmacy said suppressed competition and limited choice for physicians and patients ^[1]. GLP-1 drugs, including Novo's Ozempic and Wegovy and Lilly's Mounjaro and Zepbound, have seen a sharp rise in demand, and compounding pharmacies had stepped in to make customized versions when brand-name supply ran short ^[1].

Judge Alvarez ruled that Strive failed to plausibly describe a real product market, because compounded GLP-1 drugs are legally available only when a doctor decides a branded drug cannot meet a patient's specific medical needs. That means, in the court's view, the compounded and branded products are not interchangeable in a way that could form the basis of an antitrust claim ^[1]. The judge also found Strive did not show it was actually harmed, writing that "antitrust laws protect competition — not individual competitors — and losses attributable to ordinary competitive forces do not suffice" ^[1].

Strive said in a statement that it was disappointed by the outcome, noted that some state attorneys general had raised questions about the drugmakers' defense, and said it is evaluating options including an appeal ^[1]. Lilly said in a statement that "this meritless claim should have never been brought against Lilly" and argued the ruling "confirms that companies mass compounding tirzepatide are violating the law" ^[1]. Novo said it was "pleased with the court's decision to dismiss all claims against Novo Nordisk" and remains focused on its mission ^[1]. The case is Strive Specialties Inc v. Eli Lilly & Co and Novo Nordisk A/S et al, in the U.S. District Court for the Western District of Texas, No. 5:26-cv-00155-MA ^[1].

Why it matters for patients

The ruling is a legal defeat for compounders, one route some patients have used to get lower-cost or alternative versions of semaglutide and tirzepatide products when brand-name supply was tight or insurance did not cover the full price. The court's reasoning — that compounded drugs are legally available only in narrow circumstances tied to a doctor's determination that a branded drug won't work — could make it harder for compounding pharmacies to challenge deals between drugmakers and telehealth platforms in court ^[1].

For patients currently relying on compounded tirzepatide or semaglutide obtained through telehealth, the case does not change access rules directly, but it removes one legal avenue that compounders were using to try to preserve broader prescribing options on major telehealth platforms ^[1]. Lilly's statement framing mass compounding of tirzepatide as unlawful suggests the company may use the ruling to support further actions against compounders, though the sources do not detail what those actions might be ^[1].

What happens next

Strive said it is considering an appeal but has not announced a decision ^[1]. It is not yet known from available sources whether other compounding pharmacies face similar suits, how state attorneys general who questioned the drugmakers' defense might respond, or whether the ruling will affect telehealth platforms' current prescribing agreements with Lilly and Novo ^[1].